French neuromuscular disease biotech Dynacure officially withdraws $100 million US IPO, Dynacure, a French Phase 1/2 biotech developing therapies for neuromuscular diseases, withdrew its plans for an initial public offering on Monday, following its postponement last week. It had filed to raise $100 million by offering 6.3 million shares at a price range of $15 to $1,

Dynacure, a French Phase 1/2 biotech developing therapies for neuromuscular diseases, withdrew its plans for an initial public offering on Monday, following its postponement last week. It had filed to raise $100 million by offering 6.3 million shares at a price range of $15 to $1

, , Renaissance Capital, {authorlink}, https://www.nasdaq.com/articles/french-neuromuscular-disease-biotech-dynacure-officially-withdraws-%24100-million-us-ipo, https://www.nasdaq.com/feed/rssoutbound?category=IPOs, IPOs Feed,

This feed is responsible for generating the rss feed related to the topic ipos

, , IPO Calendar, 45, July 19, 2021, 10:04 pm

By A Silva

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.